These Analysts Lower Their Forecasts On AdaptHealth Following Weak Sales

Benzinga · Nov 7, 2024 03:13

AdaptHealth Corp. (NASDAQ:AHCO) reported worse-than-expected third-quarter sales and revised its FY24 net revenue guidance on Tuesday.

AdaptHealth reported quarterly sales of $805.86 million which missed the analyst consensus estimate of $809.30 million.

Suzanne Foster, Chief Executive Officer of AdaptHealth, stated, "I continue to be optimistic about the road ahead. We have identified growth opportunities, we are assembling a high performing team and investing in areas that allow us to serve even more patients in their homes."

AdaptHealth revised its FY24 net revenue outlook from $3.255 billion – $3.315 billion to $3.220 billion – $3.260 billion.

AdaptHealth shares gained 8.4% to trade at $9.95 on Wednesday.

These analysts made changes to their price targets on AdaptHealth following earnings announcement.

Baird analyst Eric Coldwell maintained AdaptHealth with an Outperform and lowered the price target from $16 to $14.
Canaccord Genuity analyst Richard Close maintained the stock with a Buy and cut the price target from $14 to $13.
UBS analyst Whit Mayo maintained AdaptHealth with a Buy and lowered the price target from $13 to $12.

Considering buying AHCO stock? Here's what analysts think:

Amazon, Disney, DuPont, Leidos And A Financial Stock On CNBC's 'Final Trades'

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

These Analysts Lower Their Forecasts On AdaptHealth Following Weak Sales

Risk Disclaimer